ALL INDIA INSITITUTE OF MEDICAL SCIENCES

RISHIKESH

Patient name: UHID: Admitted location:

Hospital Treatment Policy – "Remdesivir" Information Sheet (10.04.2021 onwards)

Method of how to get the drug

While choosing any experimental therapy (CP, IFN, Tocilizumab, Remdesivir, etc) for any patient as per shared guidance flow chart, once treating faculty/SR decides the drug to be indented from sub-pharmacy/blood bank at own area, treating faculty/SR has to print this page, tick on the indication, cross on contra-indications, tick on each side effects/warnings after explaining to patient/relatives, write name of patient with UHID no and patient admitted location, sign this page, take another sign from one witness person (NO/doctor not treating this pt), sign on behalf of relative after telephonically consent obtained, then submit a copy at sub-pharmacy store/blood bank to obtain the drug for total doses and keep one copy with patient e-hospital file.

Indications in COVID-19:

- Any deteriorating Mod-Severe patients (SPO2<94%) with symptom onset <7days, not requiring invasive ventilation
- Deteriorating Covid pneumonia (majorly consolidation, not ground glassing) with symptom onset <7days, not requiring invasive ventilation

Contraindications:

- Pregnancy or breast feeding
- Hepatic cirrhosis; ALT/AST > five times the upper limit of normal
- Known severe renal impairment (estimated glomerular filtration rate <30 mL/min per 1·73 m2) or receipt of continuous renal replacement therapy, haemodialysis, or peritoneal dialysis
- Hypersensitivity to remdesivir or any component of the formulation

Dose schedule & Administration:

- ≥40 kg Or Adult: Intravenous: **200 mg as a single dose on day 1, followed by 100 mg once daily**

  In Infants, Children, and Adolescents:

Sign of treating faculty/SR *Sign of Patient care taker (consented)* Sign of Witness

≥3.5 kg to <40 kg: Loading dose: 5 mg/kg/dose on day 1, followed by 2.5 mg/kg once daily.

- Administration: Administer as an IV infusion over 30 to 120 minutes. Flush the line with at least 30 mL NS after remdesivir infusion is complete. Do not administer simultaneously with any other medication or IV solutions other than Normal saline
- Duration: **5-days**

Warnings/precaution:

- Remdesivir can cause hyperglycaemia, so blood sugars should be monitored
- Chloroquine and HCQ may diminish the therapeutic effect of remdesivir hence combination of these two drugs should be avoided

Monitoring parameters:

- CBC, LFT (TB/ALT/SGOT/SGPOT), KFT (Creatinine, serum electrolytes), RBS should be done at baseline and daily during remdesivir administration

References:

1. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet. 2020 Apr 29.
2. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov
3. WHO Solidarity Trial Consortium. Repurposed antiviral drugs for covid-19—interim WHO Solidarity trial results. 15 Oct 2020. doi:10.1101/2020.10.15.20209817.
4. Beigel J, Tomashek K, Dodd LE, et al. Remdesivir for the treatment of covid-19—final report. N Engl J Med 2020 Oct 8. doi:10.1056/NEJMoa2007764. https://www.nejm.org/doi/pdf/10.1056/NEJMoa2007764.

Sign of treating faculty/SR *Sign of Patient care taker (consented)* Sign of Witness